About Us
At the Forefront of Developing
Novel Apoptosis Targeting Therapies
Ascentage Pharma is a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases. The company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
Ascentage Pharma has built a pipeline of eight drug candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company has conducted 28 Phase I/II clinical trials to evaluate the eight products in the United States, Australia and China, developing the potential therapies as a single agent or in combination.
Founders have been dedicated to apoptosis targeting drug innovation
for one decade
Company Culture
Mission
To discovery and development of innovative first- and best-in-class therapies to address unmet medical needs globally.
Vision
To become a fully integrated globally-focused biotechnology company.
Value
Patients First
Innovation-Driven
Science-Based
Founded in 2009,
Ascentage Pharma is headquartered in Suzhou, China
